Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 14/20 | 0.39 |
| ▸ | JAK3 | P52333 | 14/20 | 0.39 |
| ▸ | JAK1 | P23458 | 8/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.38 |
| ▸ | TYK2 | P29597 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13740949 | 0.95 | ALDH1A1 (0.42) | JAK2JAK3JAK1MEN1ALDH1A1 | |
| SCHEMBL12384552 | 0.95 | ALDH1A1 (0.42) | JAK2JAK3JAK1MEN1ALDH1A1 | |
| SCHEMBL19229730 | 0.81 | EPHX2 (0.46) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL12424461 | 0.80 | ALDH1A1 (0.57) | CTSBCTSSCTSKMEN1ALDH1A1 | |
| SCHEMBL20937371 | 0.80 | EPHX2 (0.49) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL23204332 | 0.78 | CHRNB2 (0.42) | — | |
| SCHEMBL23513629 | 0.78 | KDM5A (0.43) | JAK2JAK3JAK1CTSKTYK2 | |
| SCHEMBL15827186 | 0.76 | EPHX2 (0.44) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL24844030 | 0.76 | ALDH1A1 (0.44) | JAK2JAK3JAK1MEN1ALDH1A1 | |
| SCHEMBL12384822 | 0.76 | EPHX2 (0.44) | MEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | JAK2 122/4885JAK3 780/4885JAK1 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.